For laboratory and educational research use only. Not medical advice.
Women's Peptide Research
Ask Vera
Home  /  Peptide Database

Peptide database

Browse and explore comprehensive, sex-disaggregated peptide profiles.

91 peptides indexed · 82 reviewedASK VERA
91 results · full catalog
2
2X Blend CJC-1295 WO DAC (5mg) / Ipamorelin
CAS CJC-1295 WO DAC: 863288-34-0; Ipamorelin: 170851-70-4

The 2X Blend combines two complementary secretagogue research peptides, CJC-1295 (a GHRH analog) and Ipamorelin (a selective ghrelin/GHS-receptor agonist), in…

Typical dose
N/A
Route
blend, see ingredients
View ↗
4
4X Blend (Methionine / Choline / Carnitine / Dexpanthenol)
CAS Methionine: 63-68-3; Choline: 62-49-7; L-Carnitine: 541-15-1; Dexpanthenol: 81-13-0

The 4X Blend is a research preparation combining four metabolic cofactors, methionine, choline chloride, carnitine, and dexpanthenol (provitamin B5), in a…

Typical dose
N/A
Route
blend, see ingredients
View ↗
5
5-Amino-1MQ
5-amino-1-methylquinolinium
nnmt-inhibitormetabolicpreclinical

5-Amino-1MQ is a small-molecule inhibitor of the enzyme NNMT investigated for metabolic and muscle effects.

Typical dose
No established human dose; NNMT inhibition characterized in cell and rodent models only.
Route
oral
D2 of 3 female-tagged
3 studies ↗
8
8X Blend (L-Carnitine / L-Arginine / Methionine / Inositol / Choline / B6 / B5 / B12)
CAS L-Carnitine: 541-15-1; L-Arginine: 74-79-3; Methionine: 63-68-3; Inositol: 87-89-8; Choline: 62-49-7; B6 (pyridoxine): 65-23-6; B5 (dexpanthenol): 81-13-0; B12: 68-19-9

The 8X Blend is a research preparation combining eight metabolic cofactors, L-carnitine, L-arginine, methionine, inositol, choline, vitamin B6 (pyridoxine),…

Typical dose
N/A
Route
blend, see ingredients
View ↗
A
Abaloparatide
BA058
bonemenopauseosteoporosis

Abaloparatide is a synthetic analog of parathyroid hormone-related protein (PTHrP) approved in 2017 for postmenopausal osteoporosis at high fracture risk.

Typical dose
Approved labeling is 80 mcg subcutaneously once daily. This site does not publish personal dosing; the figure is the approved label value, given under prescription.
Route
subcutaneous
A168 of 388 female-tagged
388 studies ↗
A
ACE-031
Ramatercept
myostatin-inhibitoractriib-fcdiscontinued

ACE-031 (ramatercept) is a soluble activin receptor type IIB–Fc fusion designed to inhibit myostatin signaling and increase muscle mass.

Typical dose
Subcutaneous dosing was studied in early trials before the program was discontinued; not an established dose.
Route
subcutaneous
C11 of 48 female-tagged
48 studies ↗
A
Adipotide
Prohibitin-TP01
pro-apoptoticanti-obesitypreclinical

Adipotide is a peptidomimetic that targets the blood supply of white fat, causing weight loss in obese animals (including monkeys).

Typical dose
No established human dose; weight loss shown in animal models, with dose-limiting kidney effects noted.
Route
subcutaneous
D2 of 4 female-tagged
4 studies ↗
A
AICAR
Acadesine
ampk-activatorexercise-mimeticwada-banned

AICAR is an AMPK activator studied clinically as acadesine for cardioprotection (reaching Phase 3 in cardiac surgery) and preclinically as an 'exercise…

Typical dose
Intravenous acadesine regimens were used in cardiac-surgery trials; no established dose for metabolic or performance use.
Route
intravenous
B329 of 2,496 female-tagged
2496 studies ↗
A
AOD-9604
hGH Fragment 176-191 (modified)
hgh-fragmentlipolysisfailed-trials

AOD-9604 is a modified fragment of human growth hormone (176–191) originally developed as an anti-obesity agent.

Typical dose
Up to ~1 mg/day oral studied in Phase 2 obesity trials; no efficacious dose established.
Route
oral
C3 of 22 female-tagged
22 studies ↗
A
ARA-290 (Cibinetide)
Cibinetide
tissue-repairepo-derivedneuropathy

ARA-290 (cibinetide) is a non-erythropoietic peptide derived from erythropoietin, studied in small Phase 2 trials for small-fiber neuropathy (including in…

Typical dose
4 mg/day subcutaneous in Phase 2 neuropathy trials; investigational.
Route
subcutaneous
C13 of 34 female-tagged
34 studies ↗
A
Arginine Vasopressin
AVP
hormoneantidiureticapproved

Arginine vasopressin is the body's antidiuretic hormone; its synthetic form (vasopressin injection) is FDA-approved for vasodilatory shock and diabetes…

Typical dose
Weight-based intravenous infusions per approved labels (shock, diabetes insipidus); not a self-administered research dose.
Route
intravenous
A4,072 of 12,241 female-tagged
12241 studies ↗
A
Argireline
Acetyl Hexapeptide-8
cosmetic-peptidetopicalanti-wrinkle

Argireline (acetyl hexapeptide-8) is a topical cosmetic peptide marketed to soften expression lines.

Typical dose
Used topically (commonly ~5–10% in cosmetic formulations); no systemic dose and limited clinical efficacy data.
Route
topical
D7 of 45 female-tagged
45 studies ↗
B
BPC-157
Body Protection Compound 157
gastric-pentadecapeptideangiogenesistendon

BPC-157 is a synthetic pentadecapeptide widely discussed for tissue healing.

Typical dose
Reported in animal studies only; no established human dose.
Route
subcutaneous
D21 of 211 female-tagged
211 studies ↗
B
Bremelanotide (PT-141)
PT-141
melanocortin-agonistlibidofda-approved

Bremelanotide is a melanocortin receptor agonist FDA-approved (as Vyleesi) for acquired, generalized hypoactive sexual desire disorder in premenopausal women,…

Typical dose
1.75 mg subcutaneous, as-needed (per approved label)
Route
subcutaneous
A51 of 111 female-tagged
111 studies ↗
B
Bromantane
Ladasten
actoprotectorstimulant-adaptogenapproved-ex-us

Bromantane is an 'actoprotector' developed in Russia and approved there (as Ladasten) for asthenic conditions, combining mild stimulant and anxiolytic effects.

Typical dose
Oral doses (e.g., ~50–100 mg/day) are described in the Russian literature; not approved outside those markets.
Route
oral
C16 of 62 female-tagged
62 studies ↗
C
Cagrilintide
AM833
amylin-analoginvestigationalmetabolic

Cagrilintide is a long-acting amylin analog in clinical development for weight management, frequently studied combined with semaglutide (CagriSema).

Typical dose
Investigational once-weekly subcutaneous dosing in trials (literature figures, not advice).
Route
subcutaneous
B18 of 109 female-tagged
109 studies ↗
C
Cagrilintide (2.5mg) / GLP-1 S
CAS Cagrilintide: 1415456-99-3; Semaglutide: 910463-68-2

FOR RESEARCH PURPOSES ONLY.

Typical dose
N/A
Route
blend, see ingredients
View ↗
C
Cagrilintide (5mg) / GLP-1 S
CAS Cagrilintide: 1415456-99-3; Semaglutide: 910463-68-2

<p>FOR RESEARCH PURPOSES ONLY.

Typical dose
N/A
Route
blend, see ingredients
View ↗
C
Calcitonin (salmon)
salcatonin
bonemenopauseosteoporosis

Salmon calcitonin is a 32 amino acid hormone once widely used for postmenopausal osteoporosis.

Typical dose
Approved labeling for the nasal spray is 200 IU daily, alternating nostrils. This site does not publish personal dosing; use is restricted to patients for whom other therapies are unsuitable.
Route
intranasal
A674 of 1,852 female-tagged
1852 studies ↗
C
CCK-8
Cholecystokinin Octapeptide
gut-peptidesatietyapproved-diagnostic

CCK-8 is the active octapeptide of cholecystokinin, a gut hormone central to satiety and digestion.

Typical dose
Sincalide is given by weight-based intravenous infusion for diagnostic gallbladder testing per its approved label.
Route
intravenous
A6,446 of 32,441 female-tagged
32441 studies ↗
C
Cerebrolysin
FPF-1070
neuropeptide-preparationneuroprotectiveapproved-ex-us

Cerebrolysin is a porcine-brain-derived peptide preparation used clinically in many countries for stroke, traumatic brain injury, and dementia.

Typical dose
Intravenous courses (e.g., ~10–30 mL/day) are used in the countries where it is marketed; investigational in the US.
Route
intravenous
B172 of 629 female-tagged
629 studies ↗
C
CJC-1295 with DAC
CJC-1295 DAC
ghrh-analoggh-secretagoguelong-acting

CJC-1295 with DAC is a long-acting GHRH analog whose drug-affinity-complex modification extends its half-life by binding serum albumin.

Typical dose
No approved dose; limited human pharmacokinetic data only.
Route
subcutaneous
C2 of 32 female-tagged
32 studies ↗
C
CJC-1295 Without DAC
Mod GRF 1-29
ghrh-analoggh-secretagogue

CJC-1295 without DAC (Modified GRF 1-29) is a short-acting growth-hormone-releasing hormone analog used as a tool compound in secretagogue research.

Typical dose
Reported in research contexts only; no established human dose.
Route
subcutaneous
D1 of 5 female-tagged
5 studies ↗
D
Davunetide
NAP
neuroprotectivemicrotubulefailed-phase3

Davunetide (NAP) is a neuroprotective peptide studied for tauopathies; a large Phase 2/3 trial in progressive supranuclear palsy failed to meet its endpoints.

Typical dose
Intranasal dosing was used in the Phase 2/3 program; investigational, no approved dose.
Route
intranasal
B24 of 102 female-tagged
102 studies ↗
D
Dihexa
PNB-0408
angiotensin-iv-analoghgf-cmetpreclinical

Dihexa is an angiotensin IV-derived peptide studied preclinically for synapse formation and cognition via the HGF/c-Met system.

Typical dose
No established human dose; cognitive effects shown in animal models.
Route
oral
D0 of 17 female-tagged
17 studies ↗
D
DSIP
Delta Sleep-Inducing Peptide
neuropeptidesleepneuroendocrine

DSIP (delta sleep-inducing peptide) is a naturally occurring nonapeptide investigated for sleep, stress, and neuroendocrine effects.

Typical dose
No standardized human dose; small older studies used varied intravenous regimens.
Route
intravenous
C75 of 462 female-tagged
462 studies ↗
E
Epitalon
Epithalon
tetrapeptidepineallongevity-claim

Epitalon is a synthetic tetrapeptide based on the pineal peptide epithalamin, studied primarily by a single research group for aging- and telomerase-related…

Typical dose
No established dose; reported in limited studies only (not advice).
Route
subcutaneous
E65 of 212 female-tagged
212 studies ↗
F
Follistatin-344
FS-344
myostatin-inhibitorfollistatin-isoformpreclinical

Follistatin-344 is an isoform of the natural myostatin/activin antagonist follistatin, studied preclinically (including via gene therapy) for muscle growth.

Typical dose
No established human dose; muscle effects shown in preclinical and gene-therapy models.
Route
subcutaneous
D4 of 12 female-tagged
12 studies ↗
F
FOXO4-DRI
FOXO4 D-Retro-Inverso
senolyticfoxo4-p53preclinical

FOXO4-DRI is a D-retro-inverso peptide designed to disrupt the FOXO4–p53 interaction and selectively clear senescent cells (a 'senolytic').

Typical dose
No established human dose; senolytic activity shown in preclinical models only.
Route
intravenous
D1 of 18 female-tagged
18 studies ↗
G
GDF-11
Growth Differentiation Factor 11
tgf-betaagingresearch-protein

GDF-11 is a TGF-β-family protein studied for contested roles in aging and tissue rejuvenation.

Typical dose
No established human dose; used as a research protein in preclinical (cell and animal) models only.
Route
subcutaneous
D112 of 658 female-tagged
658 studies ↗
G
GDF-8 (Myostatin)
Myostatin
myostatintgf-betamuscle-regulator

GDF-8, better known as myostatin, is an endogenous TGF-β-family protein that limits skeletal-muscle growth.

Typical dose
No established human dose; used as a research protein in preclinical (cell and animal) models only.
Route
subcutaneous
D934 of 4,330 female-tagged
4330 studies ↗
G
GHK-Cu
Copper Tripeptide-1
copper-peptideskincollagen

GHK-Cu is a copper-binding tripeptide with the most human evidence in topical cosmetic use, including female-majority dermatology studies.

Typical dose
Topical formulations in cosmetic studies; systemic dosing not established.
Route
topical
C0 of 81 female-tagged
81 studies ↗
G
GHRP-2
Pralmorelin
gh-secretagoguediagnosticapproved-ex-us

GHRP-2 (pralmorelin) is a growth-hormone secretagogue approved in Japan as a diagnostic agent for growth-hormone deficiency.

Typical dose
A single ~100 µg intravenous dose is used in the approved Japanese GH-stimulation test; no approved therapeutic dose.
Route
intravenous
B80 of 221 female-tagged
221 studies ↗
G
GHRP-6
Growth Hormone-Releasing Peptide 6
gh-secretagogueghrelin-receptorresearch

GHRP-6 is a growth-hormone secretagogue studied in human pharmacology for growth-hormone release and, more recently, tissue-protective effects.

Typical dose
Microgram-per-kilogram doses used in short-term human GH-response studies; no approved therapeutic dose.
Route
subcutaneous
C163 of 671 female-tagged
671 studies ↗
G
GLOW - GHK-Cu (50mg) / BPC-157 (10mg) / TB500
CAS GHK-Cu: 49557-75-7; BPC-157: 137525-51-0; TB500: 77591-33-4

The GLOW Blend combines three widely studied research peptides, GHK-Cu, BPC-157, and TB-500 (thymosin beta-4), in one lyophilized vial for multi-pathway…

Typical dose
N/A
Route
blend, see ingredients
View ↗
G
Glutathione
GSH
antioxidantskin-lighteningtripeptide

Glutathione is an endogenous antioxidant tripeptide marketed as an oral, IV, and topical 'skin-lightening' agent.

Typical dose
Regimens vary widely (e.g., ~250–500 mg/day oral, or IV protocols); efficacy and safety of high-dose IV use are not established.
Route
oral
C5,187 of 23,989 female-tagged
23989 studies ↗
G
Gonadorelin
Factrel
gnrhfda-approvedfertility

Gonadorelin is a synthetic form of gonadotropin-releasing hormone (GnRH, also called LHRH).

Typical dose
Diagnostic and pulsatile ovulation-induction regimens are described in the clinical literature (not advice).
Route
intravenous
A173 of 304 female-tagged
304 studies ↗
G
GPE
Glycine-Proline-Glutamate
neuroprotectiveigf-1-derivedpreclinical

GPE (glycine-proline-glutamate) is an IGF-1-derived neuroprotective tripeptide studied preclinically for brain injury and neurodegeneration.

Typical dose
No established human dose for GPE; neuroprotective effects shown in preclinical models.
Route
intravenous
D11 of 97 female-tagged
97 studies ↗
H
Hexarelin
Examorelin
gh-secretagogueghrelin-receptorcardiovascular

Hexarelin is a synthetic growth-hormone secretagogue studied in short-term human pharmacology work on growth-hormone release and cardiovascular effects; it has…

Typical dose
~1–2 µg/kg in short-term human GH and cardiovascular pharmacology studies; no approved therapeutic dose.
Route
subcutaneous
C97 of 291 female-tagged
291 studies ↗
H
HGH Fragment 176-191
hGH 176-191
hgh-fragmentlipolysispreclinical

HGH Fragment 176-191 is the unmodified C-terminal lipolytic fragment of human growth hormone.

Typical dose
No established human dose; lipolytic activity described mainly in preclinical and analog (AOD-9604) work.
Route
subcutaneous
D1 of 3 female-tagged
3 studies ↗
H
Humanin
HN
mitochondrial-derived-peptidecytoprotectivepreclinical

Humanin is a mitochondrial-derived peptide studied for cytoprotective and metabolic roles in aging.

Typical dose
No established human dose; effects shown in cell and animal models.
Route
subcutaneous
D88 of 532 female-tagged
532 studies ↗
I
IGF-1 DES
des(1-3) IGF-1
igf-1-analoglab-reagentpreclinical

IGF-1 DES is a truncated, more potent form of IGF-1 used mainly as a research reagent and, unapproved, for muscle growth.

Typical dose
No established human dose; used as a laboratory reagent, with unregulated athletic use.
Route
subcutaneous
D47 of 205 female-tagged
205 studies ↗
I
IGF-1 LR3
Long R3 IGF-1
igf-1-analoglab-reagentwada-banned

IGF-1 LR3 is a long-acting IGF-1 analog used mainly as a cell-culture reagent and, unapproved, for muscle growth.

Typical dose
No established human dose; used as a laboratory reagent, with unregulated athletic use.
Route
subcutaneous
D14 of 23 female-tagged
23 studies ↗
I
Ipamorelin
NNC 26-0161
ghrpgrowth-hormone-secretagogueghrelin-mimetic

Ipamorelin is a selective growth-hormone secretagogue studied in early human and animal work.

Typical dose
Reported in early studies; no established therapeutic dose.
Route
subcutaneous
C14 of 49 female-tagged
49 studies ↗
I
Irisin
FNDC5 fragment
myokineexerciseendogenous

Irisin is an exercise-induced myokine (cleaved from FNDC5) studied for browning of fat and metabolic and bone effects.

Typical dose
No established human dose; used as a research protein in preclinical (cell and animal) models only.
Route
subcutaneous
D787 of 2,888 female-tagged
2888 studies ↗
K
Kisspeptin-10
KP-10
gnrh-axisreproductive-signaling

Kisspeptin-10 is unusual for this database: it has been studied directly in women, in reproductive-medicine research on the GnRH axis, fertility, and…

Typical dose
Investigated in controlled research settings; no established therapeutic dose.
Route
intravenous (research)
C182 of 410 female-tagged
410 studies ↗
K
Kisspeptin-54
Metastin
reproductive-hormonegnrh-axisfemale-studied

Kisspeptin-54 is a reproductive-axis peptide that stimulates GnRH release, and, unusually for this database, it has been studied directly in women, including…

Typical dose
Bolus and infusion regimens have been studied in reproductive trials (including as an IVF trigger); investigational, no approved dose.
Route
subcutaneous
B127 of 238 female-tagged
238 studies ↗
K
KLOW - GHK-Cu (50mg) / KPV (10mg) / BPC-157 (10mg) / TB500
CAS GHK-Cu: 49557-75-7; KPV: 67727-97-3; BPC-157: 137525-51-0; TB500: 77591-33-4

The KLOW Blend combines four research peptides, GHK-Cu, KPV, BPC-157, and TB-500 (thymosin beta-4), in a single lyophilized vial for multi-pathway…

Typical dose
N/A
Route
blend, see ingredients
View ↗
K
KPV
Lysine-Proline-Valine
anti-inflammatorytripeptidemelanocortin

KPV is the C-terminal tripeptide (Lys-Pro-Val) of alpha-MSH, investigated for anti-inflammatory activity in gut and skin models.

Typical dose
No established human dose; anti-inflammatory activity characterized in preclinical models only.
Route
oral
D2 of 47 female-tagged
47 studies ↗
L
Linaclotide
Linzess
guanylate-cyclase-c-agonistibs-capproved

Linaclotide (Linzess/Constella) is an FDA-approved guanylate cyclase-C agonist for IBS with constipation and chronic idiopathic constipation, conditions…

Typical dose
72–290 µg once daily by mouth depending on indication, per the approved label.
Route
oral
A106 of 467 female-tagged
467 studies ↗
L
Liraglutide
Victoza
glp-1-agonistfda-approvedmetabolic

Liraglutide is a GLP-1 receptor agonist approved as Victoza (type 2 diabetes) and Saxenda (chronic weight management).

Typical dose
Approved labels use titrated subcutaneous daily dosing (literature figures, not advice).
Route
subcutaneous
A1,339 of 5,517 female-tagged
5517 studies ↗
L
LL-37
Cathelicidin LL-37
antimicrobial-peptidecathelicidininnate-immunity

LL-37 is the only human cathelicidin antimicrobial peptide, studied mainly as an endogenous molecule in skin, airway, and immune conditions rather than as an…

Typical dose
No established human therapeutic dose; studied endogenously and in preclinical models.
Route
topical
D501 of 2,527 female-tagged
2527 studies ↗
M
Matrixyl
Palmitoyl Pentapeptide-4
cosmetic-peptidetopicalcollagen

Matrixyl (palmitoyl pentapeptide-4) is a topical cosmetic peptide marketed to support collagen and reduce wrinkles.

Typical dose
Used topically in cosmetic formulations; no systemic dose and limited clinical efficacy data.
Route
topical
D5 of 30 female-tagged
30 studies ↗
M
Mazdutide
IBI362
glp-1-glucagondual-agonistobesity

Mazdutide is a GLP-1/glucagon dual-receptor agonist based on oxyntomodulin, developed for obesity and type 2 diabetes.

Typical dose
Up to ~9 mg subcutaneous weekly in late-stage obesity trials; recently approved in China, investigational elsewhere.
Route
subcutaneous
B8 of 46 female-tagged
46 studies ↗
M
Melanotan I
Afamelanotide
melanocortin-agonistpigmentationapproved

Melanotan I is an MC1-receptor-selective analog of alpha-MSH.

Typical dose
Afamelanotide is given as a 16 mg subcutaneous implant per approved label (EPP); cosmetic dosing is unregulated and not a recommendation.
Route
subcutaneous
A23 of 121 female-tagged
121 studies ↗
M
Melanotan II
Melanotan 2
melanocortin-agonistunregulatedpigmentation

Melanotan II is a synthetic, non-selective melanocortin receptor agonist sold illicitly as a tanning agent.

Typical dose
No approved dose; early studies used subcutaneous dosing (reported for context only, not advice).
Route
subcutaneous
C39 of 197 female-tagged
197 studies ↗
M
MK-677
Ibutamoren
gh-secretagogueghrelin-agonistoral

MK-677 (ibutamoren) is an orally active ghrelin-receptor agonist that raises growth hormone and IGF-1.

Typical dose
Once-daily oral dosing has been used in clinical studies (literature figures, not advice).
Route
oral
B25 of 117 female-tagged
117 studies ↗
M
MOTS-c
mitochondrial-derived peptide
mitochondrial-derived-peptideampkmetabolic

MOTS-c is a mitochondrial-derived peptide studied in metabolic and exercise-physiology research.

Typical dose
Reported in animal studies only; no established human dose.
Route
subcutaneous
D58 of 304 female-tagged
304 studies ↗
N
NAD+
nicotinamide adenine dinucleotide
coenzymesirtuinmitochondrial

NAD+ is a core cellular coenzyme studied in metabolism and aging research.

Typical dose
Studied across a wide range in research; no consensus therapeutic dose.
Route
intravenous
C6,110 of 57,674 female-tagged
57674 studies ↗
N
Neuropeptide S
NPS
neuropeptidearousal-anxietypreclinical

Neuropeptide S is an endogenous neuropeptide studied for arousal, anxiety, and memory, mainly in animal models.

Typical dose
No established human dose; effects shown in animal models.
Route
intranasal
D80 of 420 female-tagged
420 studies ↗
N
Noopept
GVS-111
nootropicdipeptideneuroprotective

Noopept (omberacetam) is a synthetic dipeptide nootropic developed in Russia and used there clinically for cognitive and asthenic complaints.

Typical dose
Oral doses around 10–20 mg/day are described in the Russian literature; not approved outside those markets.
Route
oral
C9 of 107 female-tagged
107 studies ↗
O
Orexin-A
Hypocretin-1
neuropeptidewakefulnessnarcolepsy

Orexin-A (hypocretin-1) is a wake-promoting neuropeptide whose deficiency causes narcolepsy.

Typical dose
Intranasal orexin-A has been used in small human studies; no established therapeutic dose.
Route
intranasal
C587 of 2,369 female-tagged
2369 studies ↗
O
Oxytocin
OT
neuropeptidereproductivefda-approved

Oxytocin is one of the most extensively female-studied compounds in this database.

Typical dose
Clinical obstetric use is under medical supervision only. Not for unsupervised research administration.
Route
intravenous (clinical)
A17,039 of 29,152 female-tagged
29152 studies ↗
P
P21 (P021)
P021
neurotrophicciliary-neurotrophic-factorpreclinical

P21 (P021) is a small neurotrophic peptide mimetic derived from ciliary neurotrophic factor, studied preclinically for neurogenesis and Alzheimer's-related…

Typical dose
No established human dose; effects shown in animal models.
Route
subcutaneous
D7 of 17 female-tagged
17 studies ↗
P
PE-22-28
Spadin analog
trek-1-blockerantidepressantpreclinical

PE-22-28 is a synthetic analog of spadin that blocks the TREK-1 potassium channel, studied preclinically for rapid antidepressant-like effects.

Typical dose
No established human dose; antidepressant-like effects shown in animal models.
Route
subcutaneous
D5 of 40 female-tagged
40 studies ↗
P
Pinealon
EDR
short-peptidebioregulatorneuroprotective

Pinealon is a short synthetic tripeptide (Glu-Asp-Arg / EDR) among the Khavinson 'short peptide bioregulators,' studied for neuroprotective effects.

Typical dose
No established human dose; studied in cell and animal models.
Route
oral
D3 of 18 female-tagged
18 studies ↗
P
Plecanatide
Trulance
guanylate-cyclase-c-agonistconstipationapproved

Plecanatide (Trulance) is an FDA-approved guanylate cyclase-C agonist for chronic idiopathic constipation and IBS with constipation, conditions that are more…

Typical dose
3 mg once daily by mouth per the approved label.
Route
oral
A22 of 125 female-tagged
125 studies ↗
P
PNC-27
p53-HDM2 membrane peptide
anticancer-peptidep53-hdm2preclinical

PNC-27 is a synthetic peptide combining a p53 HDM-2-binding domain with a membrane-penetrating sequence, studied for selectively killing cancer cells.

Typical dose
No established human dose; anticancer activity shown in preclinical models.
Route
intravenous
D7 of 23 female-tagged
23 studies ↗
P
PRL-8-53
Methyl 3-(2-(benzyl(methyl)amino)ethyl)benzoate
nootropicsingle-studyunreplicated

PRL-8-53 is a synthetic compound known almost entirely from a single 1978 human study reporting improved word retention.

Typical dose
Low oral doses were used in the single 1978 study; no established or validated dose.
Route
oral
E0 of 1 female-tagged
1 studies ↗
R
Retatrutide
GLP-3 RT
gip-glp1-glucagon-agonistweight-lossinvestigational

Retatrutide is an investigational triple GIP/GLP-1/glucagon receptor agonist in Phase 2 development for obesity.

Typical dose
Investigational; no established dose. Trial doses only.
Route
subcutaneous
B20 of 158 female-tagged
158 studies ↗
S
Secretin
ChiRhoStim (human secretin)
gut-hormoneapproved-diagnosticpancreatic

Secretin is a gut hormone that regulates pancreatic and biliary secretion; its synthetic form is FDA-approved as a diagnostic agent (pancreatic function and…

Typical dose
Weight-based intravenous dosing for the approved diagnostic (secretin stimulation) tests.
Route
intravenous
A1,932 of 7,331 female-tagged
7331 studies ↗
S
Selank
TP-7
neuropeptideanxiolytic-research

Selank is a synthetic tuftsin-analog heptapeptide studied in neuropeptide and behavioral research.

Typical dose
Reported in early studies; no established therapeutic dose in most jurisdictions.
Route
intranasal
C26 of 125 female-tagged
125 studies ↗
S
Semaglutide
Ozempic
glp-1-agonistweight-lossfda-approved

Semaglutide is a GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management, with large trials that enrolled substantial numbers of…

Typical dose
Per approved label; titrated. Reported here for reference, not as advice.
Route
subcutaneous
A1,116 of 5,189 female-tagged
5189 studies ↗
S
Semax
ACTH(4-10) analog
neuropeptidebdnfnootropic

Semax is an ACTH(4-10)-derived peptide studied in neuroscience research for effects on neurotrophic signaling.

Typical dose
Reported in early studies; no established therapeutic dose in most jurisdictions.
Route
intranasal
C33 of 206 female-tagged
206 studies ↗
S
Sermorelin
GHRH (1-29)
ghrh-analoggh-secretagogueformerly-approved

Sermorelin is a synthetic fragment of growth-hormone-releasing hormone (GHRH 1-29) formerly FDA-approved as Geref for assessing growth-hormone deficiency…

Typical dose
Historically ~0.2–0.3 mg subcutaneous for GH-deficiency testing (Geref, discontinued); no current standardized therapeutic dose.
Route
subcutaneous
B151 of 369 female-tagged
369 studies ↗
S
SLU-PP-332
ERR pan-agonist
err-agonistexercise-mimeticpreclinical

SLU-PP-332 is a small-molecule pan-agonist of the estrogen-related receptors (ERRα/β/γ) studied as an 'exercise mimetic.' The evidence is entirely preclinical…

Typical dose
No established human dose; characterized in cell and rodent models only.
Route
oral
D0 of 10 female-tagged
10 studies ↗
S
SNAP-8
Acetyl Octapeptide-3
cosmetic-peptidetopicalno-indexed-evidence

SNAP-8 (acetyl octapeptide-3) is a synthetic cosmetic peptide marketed for topical 'expression-line' use.

Typical dose
Used topically in cosmetic formulations; no established systemic dose and no clinical efficacy data.
Route
topical
E0 of 0 female-tagged
0 studies ↗
S
SS-31 (Elamipretide)
Elamipretide
mitochondrialcardiolipininvestigational

SS-31 (elamipretide) is a mitochondria-targeting peptide studied in multiple Phase 2/3 trials for primary mitochondrial myopathy, Barth syndrome, heart…

Typical dose
40 mg/day subcutaneous in several Phase 2/3 trials; investigational, not approved.
Route
subcutaneous
B87 of 458 female-tagged
458 studies ↗
S
Survodutide
BI 456906
glp-1-glucagondual-agonistmash

Survodutide (BI 456906) is a GLP-1/glucagon dual-receptor agonist in Phase 2/3 development for obesity and metabolic dysfunction-associated steatohepatitis…

Typical dose
Doses up to ~6 mg subcutaneous weekly in Phase 2 trials; investigational.
Route
subcutaneous
B10 of 71 female-tagged
71 studies ↗
T
Teriparatide
PTH(1-34)
bonemenopauseosteoporosis

Teriparatide is the first 34 amino acids of human parathyroid hormone and the first bone-anabolic drug approved for osteoporosis.

Typical dose
Approved labeling is 20 mcg subcutaneously once daily. This site does not publish personal dosing; the figure is the approved label value, given under prescription.
Route
subcutaneous
A1,826 of 4,368 female-tagged
4368 studies ↗
T
Tesamorelin
Egrifta
ghrh-analogvisceral-fatfda-approved

Tesamorelin is a growth-hormone-releasing hormone analog approved to reduce visceral fat in HIV-associated lipodystrophy.

Typical dose
Per approved label. Reported here for reference, not as advice.
Route
subcutaneous
A32 of 103 female-tagged
103 studies ↗
T
Tesofensine
NS2330
triple-reuptake-inhibitorobesityinvestigational

Tesofensine is a serotonin-noradrenaline-dopamine reuptake inhibitor that produced notable weight loss in Phase 2 obesity trials after failing as a…

Typical dose
0.25–1 mg/day oral studied in Phase 2 obesity trials; investigational.
Route
oral
B12 of 56 female-tagged
56 studies ↗
T
Thymalin
Thymus peptide complex
thymic-peptideimmunomodulatorbioregulator

Thymalin is a thymus-derived peptide preparation studied largely within the Russian gerontology and 'peptide bioregulator' tradition for immune and…

Typical dose
Russian gerontology protocols report short intramuscular courses; no standardized or independently validated human dose.
Route
intramuscular
D75 of 234 female-tagged
234 studies ↗
T
Thymogen
Glutamyl-Tryptophan
immunomodulatordipeptidebioregulator

Thymogen is a synthetic dipeptide (glutamyl-tryptophan) developed in Russia as an immunomodulator.

Typical dose
Intranasal and intramuscular regimens are described in the Russian literature; no independently standardized dose.
Route
intranasal
D26 of 89 female-tagged
89 studies ↗
T
Thymosin Alpha-1
Thymalfasin
immunomodulatorthymic-peptideapproved-ex-us

Thymosin alpha-1 is a 28–amino-acid immune-modulating peptide approved in several countries (as Zadaxin/thymalfasin) for chronic hepatitis B and as an adjuvant…

Typical dose
1.6 mg subcutaneous twice weekly in most hepatitis B trials; regimens vary by indication. Investigational in the US.
Route
subcutaneous
B183 of 626 female-tagged
626 studies ↗
T
Thymosin Beta-4 (TB-500)
TB-500
actin-bindingtissue-repair

Thymosin Beta-4 (studied as the fragment TB-500) is an actin-binding peptide investigated in cell-migration and tissue-remodeling research.

Typical dose
Reported in animal studies only; no established human dose.
Route
subcutaneous
D172 of 925 female-tagged
925 studies ↗
T
Tirzepatide
Mounjaro
gip-glp1-agonistweight-lossfda-approved

Tirzepatide is a dual GIP and GLP-1 receptor agonist approved for type 2 diabetes and weight management.

Typical dose
Per approved label; titrated. Reported here for reference, not as advice.
Route
subcutaneous
A443 of 2,288 female-tagged
2288 studies ↗
V
VIP (10-28)
VIP(10-28)
vip-fragmentresearch-probepreclinical

VIP(10-28) is a fragment of vasoactive intestinal peptide used mainly as a mechanistic probe and VIP antagonist in research, including small human…

Typical dose
No established human dose; used as a mechanistic probe/antagonist in research.
Route
intravenous
D13 of 79 female-tagged
79 studies ↗
V
VIP (Vasoactive Intestinal Peptide)
Vasoactive Intestinal Polypeptide
neuropeptidevasodilatorimmunomodulator

VIP is an endogenous neuropeptide with broad roles in vasodilation, secretion, and immune regulation, studied extensively as a signaling molecule.

Typical dose
Aviptadil was studied by intravenous and inhaled routes in trials; no established therapeutic dose.
Route
intravenous
C3,814 of 13,507 female-tagged
13507 studies ↗
W
Wolverine Blend - BPC-157 (10mg) / TB500
CAS BPC-157: 137525-51-0; TB500: 77591-33-4

The Wolverine Blend combines two of the most-studied research peptides, BPC-157 and TB-500 (thymosin beta-4), in a single lyophilized preparation for…

Typical dose
N/A
Route
blend, see ingredients
View ↗
W
Wolverine Blend - BPC-157 (5mg) / TB500
CAS BPC-157: 137525-51-0; TB500: 77591-33-4

The Wolverine Blend combines two of the most-studied research peptides, BPC-157 and TB-500 (thymosin beta-4), in a single lyophilized preparation for…

Typical dose
N/A
Route
blend, see ingredients
View ↗

About the peptide database

How many peptides are in the database?

The database indexes 91 research peptides, of which 82 have completed a full sex-disaggregated evidence review. The rest carry their research facts while the female-evidence review is written.

How is each peptide's evidence grade decided?

Every compound's A–E grade is derived from published study fields by a fixed, transparent rubric, not an opaque score. Grade A requires human evidence that included female subjects; grade E means anecdotal, in-vitro, or no indexed studies.

What does the female study count tell me?

It shows how many indexed studies included female subjects and, separately, how many reported outcomes by sex. Where no qualifying female study exists, the profile says "unstudied" rather than extrapolating from male data.

Can I search the database by symptom or goal?

Yes. Use the search box to match compound names, aliases, and research tags, or filter by research area such as hormonal, metabolic, skin, or recovery. Vera, the cited AI assistant, can also answer questions across the whole database.